<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691415</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-EPI-FAS-0537</org_study_id>
    <secondary_id>EUPAS23762</secondary_id>
    <nct_id>NCT03691415</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea</brief_title>
  <official_title>Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Post Marketing Surveillance Study in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this PMS study is to evaluate the safety and effectiveness of BELKYRA Inj.
      used according to the dose specified in the instructions for use, for the treatment of
      patients with SM fullness due to SMF, through active investigation under routine clinical
      practice
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)</measure>
    <time_frame>Baseline, Follow up visit (within 3 months of injection)</time_frame>
    <description>A validated scale used by investigators to assess SM convexity/amount of SMF. Specifically, the CR-SMFRS ranges in whole number increments from 0 (absent submental convexity) to 4 (extreme submental convexity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)</measure>
    <time_frame>Baseline, Follow up visit (within 3 months of injection)</time_frame>
    <description>Validated scale used by patients to evaluate SM size. Specifically, the PR-SMFRS asks patients to assess how much fat they have under their chins by selecting options ranging from &quot;no chin fat at all&quot; to &quot;a very large amount of chin fat&quot;.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Submental Fullness</condition>
  <arm_group>
    <arm_group_label>BELKYRA Inj.</arm_group_label>
    <description>Each patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart and follow-up within 3 months of the last treatment session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BELKYRA Inj.</intervention_name>
    <description>Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.</description>
    <arm_group_label>BELKYRA Inj.</arm_group_label>
    <other_name>Deoxycholic acid</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include adult patient is an adult (≥ 18 years of age) in South Korea
        treated with BELKYRA for the improvement of moderate to severe convexity or fullness
        associated with submental fat in adults
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible and consenting Korean patients

          -  Patients who have consented to the study and who have signed the private information
             protection act form or ICF

        Exclusion Criteria:

          -  Patients having infection at the infection sites

          -  Patients presenting evidence of causes of enlarged submental area other than localized
             submental fat (E.g.: thyroid enlargement, enlarged submental salivary glands, cervical
             lymphadenopathy, etc.)

          -  Patients participating in an interventional clinical study, currently or within 30
             days before enrollment, will not be eligible for inclusion in the study

          -  Pregnant women

          -  Renal impairment patients

          -  Hepatic impairment patients

          -  Patients with severe laxity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne St. Rose, DVM, MSc, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>877‐277‐8566</phone>
    <email>IR‐CTRegistration@Allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oracle-Dermatology</name>
      <address>
        <city>Daejeon</city>
        <zip>35234</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koeunme &amp; S-line clinic</name>
      <address>
        <city>Hwaseong-si</city>
        <zip>18453</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Yeonse Medi-Noble clinic</name>
      <address>
        <city>Seoul</city>
        <zip>04385</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Maylin- Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>06005</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Goldenview plastic surgery</name>
      <address>
        <city>Seoul</city>
        <zip>06010</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MH- Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>06010</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>(Apgujeong) Oracle-Dermatology</name>
      <address>
        <city>Seoul</city>
        <zip>06022</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dream-Dermatology</name>
      <address>
        <city>Seoul</city>
        <zip>06030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ID-Dermatology</name>
      <address>
        <city>Seoul</city>
        <zip>06039</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nana Plastic surgery</name>
      <address>
        <city>Seoul</city>
        <zip>06119</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Regen- Clinic</name>
      <address>
        <city>Seoul</city>
        <zip>06611</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com/</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR‐CTRegistration@Allergan.com for assistance.&quot;</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double Chin Fat Reduction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

